Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:05:45.382Z.
Calculation as of: 2026-10-06T15:05:45.382Z.
Quote observation: 2026-10-06T15:05:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 271c6898cd70d4c389427987313f1838723d439a48fe58857c9b6a6cb9daa9ad
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$666.04M
EV/Sales Ratio
1.50x
TTM Avg
1.59x
3Y Avg
2.50x
5Y Avg
2.28x
Market Cap
$673.11M
EV/Sales Ratio
6.98x
TTM Avg
3080.33x
3Y Avg
3087.28x
5Y Avg
1898.38x
Market Cap
$609.24M
EV/Sales Ratio
1.73x
TTM Avg
1.55x
3Y Avg
1.11x
5Y Avg
1.54x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | $642.86M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $647.30M | 16.70x | 10.41x | 12.28x | 16.01x |
| Climb Bio, Inc. (CLYM)vs › | $637.30M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $666.04M | 1.50x | 1.59x | 2.50x | 2.28x |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $673.11M | 6.98x | 3080.33x | 3087.28x | 1898.38x |
| AngioDynamics, Inc. (ANGO)vs › | $609.24M | 1.73x | 1.55x | 1.11x | 1.54x |
| Helus Pharma Inc. (HELP)vs › | $675.63M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $622.01M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $682.40M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $600.51M | 1.80x | 1.86x | 1.97x | 1.94x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
